Sitemap
- The Penn Scleroderma Center: A Leader in Scleroderma
-
Research
-
Active Research Studies
- A Randomized, Double-blind, Placebo-controlled, Repeat-dose, Multicenter Trial to Evaluate the Efficacy, Safety, Tolerability and Pharmacokinetics of HZN-825 in Patients with Diffuse Cutaneous Systemic Sclerosis
- CONQUER
- GRASP
- Evaluating X-Chromosome Inactivation Maintenance in a Cross-sectional Cohort of Patients with Systemic Sclerosis
- CARTIMMUNE: A Single-Center Study of Patients with Autoimmune Diseases Receiving an Autologous Fully-Human Anti-CD19 Chimeric Antigen Receptor T-Cell (KYV-101)
- SCTC White Paper Initiative
- A Phase 2/3, randomized, double-blind, placebo-controlled, parallel-group study to evaluate the efficacy and safety of belimumab administered subcutaneously in adults with systemic sclerosis associated interstitial lung disease (BLISSc-ILD)
- Recently Completed Research Studies
- Being a Research Participant
- Selection of Publications by the Penn Scleroderma Center
-
Active Research Studies
- Patient Care